Europe Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins

Europe Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-like peptide-1 (GLP-1), Pens and Needles, and Others)   

The insulin market in Europe is expected to grow from US$ 20,823.35 million in 2022 to US$ 38,279.77 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.
Increase in Incidence of Diabetes Bolsters Europe Insulin Market
Diabetes, a life-threatening chronic disease with no specialized cure, is mainly caused by the body’s incapacity to produce or effectively utilize the hormone insulin. This incapacity prevents the body from adequately regulating blood glucose levels. The incidence and prevalence of diabetes are rapidly increasing across Europe. Type 2 diabetes is the most prevalent form of diabetes and has grown alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to the International Diabetes Federation (IDF), ~537 million people were living with diabetes in 2021, and the number is expected to reach 643 million by 2030 and 783 million by 2045. Diabetes increases the risk of premature death of individuals by leading to complications in several body parts. Primary complications include heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Patients who have diabetes require frequent monitoring and external insulin administration. Thus, the rising prevalence of diabetes is driving the growth of the insulin market in Europe.

Market Overview

The Europe insulin market is subsegmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. The growth of the market in this region is expected to be the second largest after Germany. The prevalence of diabetes among all age groups in Europe is surging with the going commonness of obesity, unhealthy diet, and lacking physical inactivity. The prevalence of autoimmune type 1 Diabetes is rising in the region. Moreover, technologies such as insulin pumps, insulin pens, and continuous glucose monitoring devices are gaining significant acceptance in Europe. Europe has the world’s highest number of children with type 1 Diabetes. Type 1 diabetes is highly prevalent among children in the UK, Russia, and Germany. According to International Diabetes Federation (IDF), Germany has 7 million people diagnosed with diabetes, and it estimates that ~1.3 million people are expected to be living with undetected diabetes. According to the German Diabetes Centre (DDZ), diabetes would affect 12 million in the country by the end of 2040, and type 2 diabetes is anticipated to be a more prevalent type during the period.
Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)

Europe Insulin Market Segmentation

The Europe insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.
Based on long acting insulin, the Europe insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.
Based on short acting insulin and traditional human insulin, the Europe insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
Based on concentrated insulin and combination insulin, the Europe insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.
Based on biosimilar insulin, the Europe insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2022.
Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe insulin market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe insulin market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution